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ABSTRACT The influenza pandemic of 1918–1919 killed approximately 50 million people. The unusually severe morbidity and
mortality associated with the pandemic spurred physicians and scientists to isolate the etiologic agent, but the virus was not iso-
lated in 1918. In 1996, it became possible to recover and sequence highly degraded fragments of influenza viral RNA retained in
preserved tissues from several 1918 victims. These viral RNA sequences eventually permitted reconstruction of the complete
1918 virus, which has yielded, almost a century after the deaths of its victims, novel insights into influenza virus biology and
pathogenesis and has provided important information about how to prevent and control future pandemics.
The “Spanish” influenza pandemic of 1918 –1919 stands as thedeadliest single event in recorded human history, killing ap-
proximately 50 million people worldwide (1, 2). The unprece-
dented burden of morbidity and mortality frustrated physicians
and scientists, who were unable to identify the etiologic agent, but
also spurred advances in microbiology, clinical infectious diseases,
and public health practice (3). Influenza viruses were finally iso-
lated about 15 years after the pandemic, but scientists of the early
20th century were not then capable of studying the biological basis
of pandemic viral emergence, pathogenicity, or disappearance, let
alone of gaining insights that might help to prevent or mitigate
future pandemics. The cause of the 1918 pandemic and the deter-
minants of its severity remained one of the most discussed medical
mysteries throughout most of the 20th century.
Development of PCR technology in the 1980s, however, made
it possible to recover and sequence highly degraded fragments of
viral RNA retained in preserved tissues from persons who suc-
cumbed in 1918 (4–7). By use of the then-new approach of viral
“reverse genetics,” these viral RNA sequences permitted eventual
reconstruction of the complete 1918 virus (8). Remarkably, tiny
viral RNA fragments recovered from just a few of the pandemic’s
many millions of victims have yielded, almost a century after their
deaths, novel insights into influenza virus biology and pathogen-
esis and have provided important information about how to pre-
vent and control future pandemics. This year (2012) marks the
15th anniversary of the publication of the initial 1918 influenza
virus sequences (6), which led to the full genome sequence a de-
cade later. Below, we review some of the studies performed with
the 1918 virus and their implications for medical and public
health practice today.
The milestone achievement of reconstructing an “extinct”
pandemic virus raised a number of questions that had not been
asked before. The most fundamental of these was whether it was
necessary or wise to recreate by molecular means a naturally ex-
tinct virus that represented one of the deadliest infectious agents
in human history. This question was answered in the affirmative
when senior U.S. government scientists and officials at the De-
partment of Health and Human Services concluded that such re-
search could play an important role in pandemic influenza pre-
paredness (9). The U.S. government began to regulate research
with the 1918 virus through the National Select Agents Registry
Program at the U.S. Centers for Disease Control and Prevention
(CDC). Guidelines contained in the Biosafety in Microbiological
and Biomedical Laboratories (BMBL) manual (10) were quickly
modified to support development, by institutional biosafety com-
mittees, of safe protocols for biocontainment and biosafety. Re-
search with the 1918 virus has since gone forward at a rapid pace,
leading to numerous findings, some of which are highlighted be-
low. This important body of work exemplifies the benefits of
studying pathogens that have a potential for “dual use,” provided
that biosafety and biosecurity issues are adequately addressed.
Dual use research is defined as work with clear benefits for society
for which there also exists a theoretical potential for misuse (e.g.,
bioterrorism). In this commentary, we briefly review some of the
important insights into influenza virus biology and public health
that have already resulted from the sequencing and reconstruction
of the 1918 virus. We argue that learning the most closely guarded
secrets of our deadliest biological enemies is an essential means of
protecting ourselves from future events of a similar nature.
PUBLIC HEALTH CONSEQUENCES OF UNDERSTANDING THE
RELATIONSHIP BETWEEN THE 1918 AND 2009 PANDEMIC
VIRUSES
Although the pandemic influenza viruses of 1957, 1968, and 2009
are all descended, via different pathways, from the 1918 virus, only
the 2009 pandemic virus expresses an antigenically similar hem-
agglutinin (HA) (11). All influenza A viruses (IAV), including the
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1918 virus, possess a segmented single-stranded RNA genome and
can evolve by the accumulation of selected mutations (“antigenic
drift”) or through the exchange of gene segments by reassortment
with other influenza viruses (“antigenic shift”). Sequencing the
1918 virus provided the basis for the subsequent understanding
that the key 2009 virus HA gene, after having apparently been
transmitted from humans to pigs in or about 1918, had been
maintained in pigs over the past 90 years or so as a separate lineage
from the 1918 human pandemic H1N1 virus (11), a lineage that
has long been recognized as the “classical” swine H1N1 influenza
virus. When the 2009 pandemic virus emerged in humans with a
swine H1 HA gene descended from, and still closely related anti-
genically to, the 1918 pandemic virus, extensive cross-protection
between the 2009 and 1918 pandemic viruses was demonstrated in
experimental animals (12–16). Interestingly, 1918 virus-specific B
cell clones could also still be recovered from very elderly survivors
90 years after their exposure to that virus but before their exposure
to the 2009 pandemic virus (17). These findings provided a scien-
tific rationale for targeting the initial 2009 H1N1 pandemic vac-
cine to those who needed it most, predominantly younger persons
who had never been exposed to the cross-protective 1918 virus or
to its early seasonally prevalent descendants. Thus, early in the
2009 pandemic, limited vaccine that might otherwise have been
misdirected to the traditional risk group, the elderly (who were
paradoxically at much lower risk in 2009), was instead adminis-
tered to younger persons, who benefitted most.
INSIGHTS INTO NOVEL CROSS-REACTIVE INFLUENZA
VACCINE APPROACHES USING THE 1918 VIRUS
HEMAGGLUTININ STRUCTURE
Knowledge of the structure of the 1918 virus HA protein, as de-
termined by crystallography, has led to a better understanding of
influenza viral receptor binding and host adaptation and has also
provided novel insights in an unexpected direction—structure-
based vaccine design. Characterized protein motifs on the 1918
virus HA structure, conserved across many divergent HA proteins
of different subtypes, are serving as a functional basis for next-
generation vaccine approaches (18, 19) aimed at providing broad,
cross-reactive immunity to IAV of different subtypes, including
H5N1 viruses (20, 21). This knowledge has contributed to ongo-
ing, innovative research to develop “universal” influenza vaccines
that might be given infrequently yet conceivably cover all emerged
and potential future pandemic viruses. It would obviously be a
major advance if it became possible to circumvent the current
requirement for annual vaccination that is a consequence of con-
tinual antigenic drift of viral epitopes under the pressure of im-
mune selection.
INSIGHTS INTO INFLUENZA VIRUS EVOLUTION
The genomic sequence of the 1918 influenza virus has stimulated
consideration of mechanisms of viral adaptation by which human
pandemic strains emerge, including the possible role of interme-
diate mammalian hosts. Avian IAV have a higher guanine-
cytosine (GC) content than do viral strains adapted to humans
(22, 23). Gene segments from the 1918 virus have a nucleotide
composition and GC content similar to those of avian IAV. Al-
though its origin has not been fully resolved (2, 24, 25), the avian
influenza virus-like genome of the 1918 pandemic virus suggests
derivation from an avian virus in the decade before 1918, with or
without adaptation in an intermediate host (26).
The evolution of human IAV after 1918 is better understood:
all three pandemic viruses since 1918 contain gene segments de-
rived from the 1918 “founder” virus. Consequently, the past
94 years can be considered to constitute a single “pandemic era,”
with the founding 1918 pandemic virus leading to emergence of
pandemic progeny viruses in 1957, 1968, and 2009 (11, 27). The
realization that, since 1918, the 1918 virus has been the genetic
“mother of all pandemics” has also led to reexamination of the
historical record. Going back more than 500 years, evidence has
suggested the existence of earlier, seemingly analogous, pandemic
influenza eras (27), although for obvious reasons the genetic
mechanisms remain entirely unknown. This insight has led to the
hypothesis that influenza pandemic eras are initiated by extremely
uncommon IAV host switch events, in which founding viruses
arise de novo or from other yet-unknown mechanisms to cause
pandemics and then, in the face of induced population immunity,
prevail and seed new progeny pandemic viruses by genetic mech-
anisms involving mutation and reassortment. Incorporation of
one or more novel gene segments into existing postpandemic vi-
ruses allows these viruses to escape population immunity while
retaining those properties associated with human adaptation. This
implies that viral surveillance needs to look in two directions si-
multaneously: for novel influenza viruses that may emerge in hu-
mans or other mammals from the avian virus gene pool and for
existing human- and mammal-adapted viruses that may be in-
volved in gene segment recycling or further adaptational evolu-
tion.
Investigation of the origins of the 1918 influenza virus with
phylogenetic and bioinformatic studies has also led to comparison
with many other IAV genomes from avian, mammalian, and hu-
man hosts. Thus, in certain ways, the 1918 sequencing project has
served as a springboard for rapidly expanding publically available
IAV genome sequences. Such sequences have already been impor-
tant for understanding influenza virus evolution in humans and
animals (28–31) and in responding to important unexpected
events, such as the emergence of 2003 Fujian H3N2 virus (32) and
the 2009 H1N1 virus pandemic (33). While practical integration
of this new information into surveillance and public health pre-
paredness is daunting, it is leading us to a greater understanding of
the underlying patterns of influenza virus emergence and evolu-
tion and of the compendium of IAV strategies that result in adap-
tation to mammalian and human hosts. These insights in turn
should lead to an enhanced ability to anticipate, detect (e.g.,
through targeted viral surveillance), and respond to novel influ-
enza viral emergence in humans.
VIRULENCE, HOST ADAPTATION, AND TRANSMISSION
FACTORS OF THE 1918 INFLUENZA VIRUS
The fully reconstructed 1918 pandemic virus is pathogenic—
without prior adaptation—in mice (8), ferrets (34), and macaques
(35) (N.B., while mice are commonly used in experimental influ-
enza studies, disease and efficient viral replication in mice are not
generally observed with unadapted human IAV strains). To com-
bat infectious diseases, it is necessary to understand the molecular
basis of each pathogen’s phenotypic properties, including infec-
tivity, cell tropism, replication, immunogenicity, pathogenicity,
and transmissibility. Numerous pathogenicity studies have been
performed with the 1918 virus in animal models, including both
“gain-of-function” and “loss-of-function” studies using chimeric
influenza viruses carrying one or more 1918 viral genes of interest,
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expressed on less pathogenic viral “reference” backgrounds. Such
studies, while seeking primarily to answer questions about the
1918 pandemic, have provided insights into possible mechanisms
of pathogenicity and host adaptation of future pandemic strains.
Disease severity, host adaptation, and transmission are all
complex viral phenotypic properties that cannot be understood
without elucidating their genetic bases, e.g., by addition of genetic
information to a virus that lacks it (gain of function) or by removal
of that genetic trait (loss of function). Such studies have shown
convincingly that, although the innate virulence of the 1918 influ-
enza virus is polygenic, proteins encoded by the HA and the three
polymerase gene segments play key roles (8, 36–42). Despite lack-
ing any obvious single virulence factor, influenza viruses express-
ing the 1918 virus HA are unquestionably pathogenic in mice and
ferrets. Moreover, chimeric influenza viruses expressing each of
the four known pandemic virus HA proteins (1918 H1, 1957 H2,
1968 H3, and 2009 H1 subtypes) are pathogenic in mice, based in
part on their ability to replicate efficiently in lung parenchyma
(41). However, the 1918 viral HA is not the only virulence factor in
the 1918 virus. Several gain-of-function studies have shown that
IAV expressing the genes of the 1918 viral polymerase complex are
also pathogenic in mouse and ferret models (12, 36, 40, 42).
Just as evolutionary analyses have helped to clarify the relation-
ship between the 1918 virus and its pandemic viral progeny, sim-
ilar studies with the reconstructed 1918 virus have led to a fuller
understanding of host adaptation. It is becoming clear that muta-
tions associated with influenza virus host switch events may be
unique and not shared with other viruses: influenza viral host
adaptation appears to be a complex, context-dependent process,
which likely is different for each individual virus adapting to a new
host. For example, mutations associated with human adaptation
in the 1918 virus have not in general been observed in different
lineages of other human- or mammal-adapted influenza viruses,
including the 2009 pandemic virus (37, 43– 45). Therefore, in or-
der to better predict the emergence of future pandemic viruses,
structure/function correlates are critically needed to understand
the biological implications of mutation patterns associated with
new-host adaptation. Furthermore, understanding human influ-
enza virus transmissibility is complicated by the lack of ideal ani-
mal models, although ferrets, guinea pigs, and mice have all been
used for this purpose. Experiments with the 1918 virus have
shown that changes in both the HA receptor-binding domain and
the polymerase PB2 protein correlate with ferret transmissibility
(46, 47). Such studies provide valuable insights into how future
IAV, e.g., highly pathogenic avian influenza virus H5N1 strains,
might adapt to humans and become efficiently transmissible (48,
49).
UNDERSTANDING OF INFLUENZA VIRUS RECEPTOR
BINDING
Attachment of influenza viruses to target cells is mediated by HA
binding to receptor glycans terminating in sialic acids that are
linked in different configurations to underlying sugars. Although
IAV adapted to avian hosts have specificity for 2-3 sialic acid
linkages, a few critical mutations in the HA receptor-binding do-
main, as seen with most human-adapted viruses, can alter speci-
ficity to cellular glycans terminating in 2-6-linked sialic acids.
Structural analyses and in vitro binding assays with the 1918 virus
HA have confirmed that only two mutations in the receptor-
binding domain determine complete alteration of viral specificity
from avian-adapted to a human-adapted configuration (50–52).
Such information helps us predict what similar receptor-binding
mutations might be needed for a future pandemic virus to adapt
successfully to humans, thus facilitating targeted viral surveillance
(53).
Recent studies using autopsy tissues of 1918 pandemic victims
have led to the unexpected observation that both 2-3 and 2-6
receptor-binding variants of the 1918 virus cocirculated during
the first year of the pandemic (54). Does this reflect early evolution
from an avian- to a mammal-adapted virus? Did pandemic viral
quasispecies contain both variants, and if so, was this a reflection
of different cell tropisms along the human respiratory tract? Al-
though these questions cannot yet be answered, they are stimulat-
ing further experiments to evaluate how receptor-binding vari-
ants are selected within single hosts and how these variants affect
pathogenicity, host adaptation, and transmissibility.
PATHOLOGY OF INFLUENZA AND IMPORTANCE OF
COINFECTIONS
The high 1918-1919 case fatality rates prompted many clinico-
pathological studies in the aftermath of the pandemic. Reevalua-
tion of 1918 autopsy tissues in the modern era (including those
from which the viral RNA fragments were detected) has clarified
pathological changes associated with fatal influenza pneumonias
(55) and the critical role that secondary bacterial infection plays in
severe disease following influenza viral infection (56). These find-
ings have led to a burgeoning field of research in influenza virus/
bacterial copathogenesis, directed at understanding the funda-
mental mechanisms whereby viral infections and host immune
responses may potentiate secondary bacterial infections, includ-
ing inhibition of respiratory cell repair (57), and how viral altera-
tions of the immune response may affect bacterial pathogenesis
(58, 59). These findings have important implications for clinical
management and public health control. Awareness of the 1918
pandemic’s pathologic features led physicians to anticipate and
institute early antibiotic treatment of 2009 pandemic influenza
virus-infected patients who might otherwise have had fatal out-
comes due to secondary bacterial pneumonias (60).
THE ROLE OF HOST INFLAMMATORY RESPONSES IN
DISEASE PROGRESSION
The unusual “W-shaped” age-specific 1918 death curve, with a
peak of mortality in 20- to 40-year-olds, has always been one of the
1918 pandemic’s most puzzling features (2). For decades, there
has been speculation that a robust inflammatory response in oth-
erwise healthy young individuals may have been a contributing
factor. Interestingly, while not necessarily causally related to the
unusual age-specific death curve, experimental pathogenesis
studies with the 1918 virus in both mouse and nonhuman primate
models support the hypothesis that aspects of the innate host re-
sponse may be involved in disease progression. In mice, the 1918
virus induces a profound activation of inflammatory and cellular
death receptor response mechanisms (38). Similarly, 1918 virus
infection of macaques is associated with the suppression of type I
interferon responses and a concomitant increase in expression of
proinflammatory chemokines (35). Thus, the 1918 influenza virus
is efficient at suppressing innate antiviral responses while concur-
rently activating potent proinflammatory responses. In recent
work, the 1918 virus was used to characterize a novel open reading
frame encoded by IAV. This newly identified viral protein, appar-
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ently a product of all influenza A viruses, seems to modulate the
host response to infection, a finding with important implications
both for understanding IAV pathogenesis and in developing new
ways to treat influenza viral infection (61). Together, these obser-
vations point to avenues for further research that may ultimately
lead to new treatments aimed at suppressing immunopathogenic
responses to IAV infection.
CONCLUSIONS
Like other fields in which studying the past helps to understand
the present, virology is now finding a wealth of important infor-
mation hidden in very degraded RNA viral fragments from a long-
ago pandemic. The 1918 pandemic has long been a benchmark for
medical historians as they seek to understand tragic events that
were incomprehensible at the time. Now, virologists and allied
scientists are providing the biological insights that strengthen his-
torical understanding. But, however important understanding the
past may be, it is the promise of managing the future that we insist
is most compelling. Sequencing the genome of the 1918 pandemic
virus has opened a once-locked door that allows us to use the past
to better understand the future. The benefits of this work include
not only fuller understanding of one of the deadliest of human
diseases but also practical clinical and public health knowledge
that can save lives and improve health today. While challenges
remain, opportunities for additional discovery abound, not just in
work to prevent and mitigate future pandemics but also in con-
tinuing to look backward, even before 1918, to gain insights into
the larger-scale behaviors and strategies of pandemic influenza
viruses as they have been played out over centuries. Although
concern about dual use research was considered from the begin-
ning of the 1918 viral sequencing project through the complete
sequence and reconstruction of the pandemic virus, no adverse
events have occurred. On the contrary, the benefits are obvious
and manifold and have demonstrably contributed to the better-
ment of human health. Reconstruction of the 1918 virus has al-
ready been unexpectedly rewarding. Unquestionably, even greater
rewards lie ahead.
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